A PHASE I, OPEN LABEL, DOSE-ESCALATION TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF GcMAF (GLOBULIN COMPONENT MACROPHAGE ACTIVATING FACTOR) IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES

Trial Profile

A PHASE I, OPEN LABEL, DOSE-ESCALATION TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF GcMAF (GLOBULIN COMPONENT MACROPHAGE ACTIVATING FACTOR) IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Vitamin D-binding protein-macrophage activating factor (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Efranat
  • Most Recent Events

    • 18 Jun 2017 Status changed from recruiting to completed.
    • 11 Oct 2015 Planned End Date changed from 1 May 2016 to 1 May 2017, as reported by ClinicalTrials.gov.
    • 11 Oct 2015 Planned primary completion date changed from 1 May 2015 to 1 May 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top